Kolkata: Indian stock market continued on its downward journey on Thursday, January 9, 2025 with unabated selling pressure from Foreign Institutional Investors, who have been selling Indian equities since October 2024. Sensex slipped 528.28 points (or 0.68%) to reach 77,620.21 points while Nifty declined 162.45 points (0.69%) to close the day at 23,526.50 points.
On Thursday, January 9, 2025, in the 30-share Sensex the top losers were ONGC, Shriram Finance, BPCL. Coal India etc. The top prominent gainers included Nestle, HUL, M&M and Britannia. Here are the stock that are likely to remain in focus on Friday, January 10, 2025.
TCS: India’s largest software company, TCS, beat estimates by a small margin when on Thursday, January 9, it reported consolidated PAT of Rs 12,380 crore for Q3 (the October-December quarter) recording a rise of 12%. The comparable figure for the same period a year ago was Rs 11,058 crore. The results of TCS flags off the quarterly earnings season in India.
IREDA: PSU Indian Renewable Energy Development Agency (IREDA), that finances projects in renewable energy, reported a 26.8% y-o-y rise in its net profit for Q3 of FY25. The results were declared on Thursday, January 9, 2025. The net profit stood at Rs 425.4 crore compared to Rs 335.5 crore compared to the Q3 PAT figure in FY24. IREDA’s net interest income also zoomed 39% (y-o-y) and stood at Rs 622.3 crore, up from Rs 448.1 crore in the same period last year.
Tata Elxsi: On Thursday, January 9, 2025, Tata Elxsi announced a decline in net profit for Q3 in FY25. The rate of decline was 3.39% and the amount stood at Rs 199 crore for the October-December period compared to Rs 206 crore in the October-December of FY24. However, revenue of the company rose 2.72% to touch Rs 939.17 crore in Q3 against a figure of Rs 914.23 crore in the comparable quarter of FY24. Operating profit was recorded at Rs 246.6 crore in Q3 – the EBITDA margin was at 26.3%.
Lupin Laboratories: Lupin said that it received a tentative approval from the US FDA to market its generic version of Ivacaftor oral granules which is used in treatment of cystic fibrosis. Lupin may become eligible for 180 days of generic drug exclusivity. The item will be manufactured at Lupin’s Nagpur facility. According to reports, Ivacaftor Oral Granules are prescribed for the treatment of cystic fibrosis, a genetic disease that causes the body to produce thick mucus. It can be administered in patients aged four months and older who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that responds to ivacaftor.
(Disclaimer: This article is only meant to provide information. News9 does not recommend buying or selling shares or subscriptions of any IPO and Mutual Funds.)
Stocks in News Today: From TCS to Lupin Laboratories here are the stocks that are likely to remain in focus on Friday, January 10, 2025. Sensex and Nifty continued its decline on January 9, with the BSE index dropping 0.68% to and NSE index declining 0.69% at close of trade. Markets Business News – Personal Finance News, Share Market News, BSE/NSE News, Stock Exchange News Today
